Kluwer Competition Law Blog
Innovation Competition in EU Merger Control: The Commission in Pursuit of a New Greater Good?
January 23, 2018
The European Commission’s recent focus on the impact of mergers on innovation competition has sparked a heated debate amongst lawyers and economists. Innovation seems to have become the new “Greater Good” the Commission is pursuing when reviewing mergers, whether in the pharmaceutical or medical device sectors, in pesticides, engineering, ICT or other technology-driven industries.
This article was originally published on Kluwer Competition Law Blog.
得意分野
Suggested News & Insights
Sidley Represents Rigel Pharmaceuticals in Exclusive Global License Agreement with Pfizer and Arvinas for VEPPANUMay 13, 2026Sidley Represents Private Equity at Goldman Sachs Alternatives in the Acquisition of FGI WorldwideMay 12, 2026When “The Devil Made Me Do It” Is Not a Defense: Lessons in AI Governance and Organizational Oversight from an SDNY DecisionMay 11, 2026Sidley Represents Siris Capital in Its US$4.2 Billion Sale of EquinitiMay 5, 2026April Antitrust and Competition Bulletin: Top-of-Mind Global Antitrust IssuesApril 23, 2026Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement FinancingApril 21, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
